David M O'Malley Selected Research

mirvetuximab soravtansine

1/2020	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
1/2019	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
10/2018	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
1/2018	A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
8/2017	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
4/2017	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David M O'Malley Research Topics

Disease

60	Ovarian Neoplasms (Ovarian Cancer) 12/2022 - 08/2005
43	Neoplasms (Cancer) 12/2022 - 01/2009
28	Carcinoma (Carcinomatosis) 01/2022 - 07/2004
16	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 12/2008
16	Ovarian Epithelial Carcinoma 01/2021 - 08/2005
8	Neutropenia 12/2022 - 05/2014
8	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 07/2004
7	Disease Progression 01/2022 - 05/2010
6	Fatigue 01/2022 - 01/2017
6	Fallopian Tube Neoplasms 01/2022 - 02/2016
5	Anemia 12/2022 - 07/2004
4	Hypertension (High Blood Pressure) 01/2022 - 02/2016
3	Nausea 01/2022 - 11/2017
3	Microsatellite Instability 01/2022 - 01/2021
3	Neoplasm Metastasis (Metastasis) 11/2021 - 07/2009
3	Hypersensitivity (Allergy) 12/2020 - 01/2017
2	Vulvar Neoplasms (Vulvar Cancer) 11/2021 - 10/2014
2	Asthenia 01/2021 - 11/2017
2	Infections 01/2019 - 01/2017
2	Leiomyosarcoma 10/2018 - 04/2015
2	Febrile Neutropenia 01/2018 - 01/2017
2	Thrombocytopenia (Thrombopenia) 02/2016 - 07/2004
2	Carcinosarcoma 06/2014 - 05/2010
2	Adenocarcinoma 12/2008 - 12/2008
1	Exanthema (Rash) 01/2022
1	Neoplasm Micrometastasis 11/2021
1	Inflammation (Inflammations) 11/2021
1	Cicatrix (Scar) 01/2021
1	Trophoblastic Neoplasms (Trophoblastic Tumor) 05/2020
1	Ileus 01/2020
1	COVID-19 01/2020
1	Kidney Neoplasms (Kidney Cancer) 01/2020
1	Residual Neoplasm 12/2019

Drug/Important Bio-Agent (IBA)

41	PlatinumIBA 12/2022 - 11/2008
19	Bevacizumab (Avastin)FDA Link 05/2022 - 12/2008
19	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2004
18	Paclitaxel (Taxol)FDA LinkGeneric 12/2022 - 03/2009
17	rucaparibIBA 12/2022 - 01/2017
14	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2017
7	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 04/2017
6	mirvetuximab soravtansineIBA 01/2020 - 04/2017
5	taxaneIBA 12/2022 - 11/2008
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2018
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 01/2017
4	Monoclonal AntibodiesIBA 12/2021 - 04/2017
4	AntigensIBA 01/2021 - 11/2016
4	Folate Receptor 1IBA 01/2020 - 04/2017
4	Gemcitabine FDA Link 10/2018 - 12/2008
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2020
3	veliparibIBA 01/2022 - 02/2016
3	balstilimabIBA 01/2022 - 09/2021
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 07/2004
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2005
3	Docetaxel (Taxotere)FDA Link 10/2018 - 10/2009
2	Poly Adenosine Diphosphate RiboseIBA 05/2022 - 01/2021
2	niraparibIBA 01/2022 - 01/2019
2	pembrolizumabIBA 01/2022 - 01/2021
2	Topotecan (Hycamtin)FDA LinkGeneric 11/2021 - 08/2005
2	1-dodecylpyridoxal (PLD)IBA 11/2021 - 02/2016
2	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 02/2016
2	olaparibIBA 01/2021 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 10/2018
2	TubulinIBA 01/2020 - 04/2017
2	Maytansine (Maitansine)IBA 01/2020 - 04/2017
2	Pharmaceutical PreparationsIBA 01/2020 - 02/2016
2	pegfilgrastim (Neulasta)FDA Link 01/2018 - 09/2015
2	Cisplatin (Platino)FDA LinkGeneric 05/2011 - 10/2009
1	Taxoids (Taxanes)IBA 12/2022
1	paclitaxel poliglumex (XYOTAX)IBA 12/2022
1	dostarlimabIBA 01/2022
1	trametinibIBA 01/2022
1	NivolumabIBA 12/2021
1	Death Domain ReceptorsIBA 12/2021
1	PM 01183IBA 11/2021
1	Cytotoxins (Cytolysins)IBA 01/2021
1	CreatinineIBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	lenvatinibIBA 01/2021
1	binimetinibIBA 11/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	chemotactic factor inactivatorIBA 01/2020
1	XL765IBA 01/2020
1	budigalimabIBA 01/2020
1	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 01/2020

Therapy/Procedure

44	Drug Therapy (Chemotherapy) 12/2022 - 07/2004
36	Therapeutics 12/2022 - 12/2008
7	Radiotherapy 11/2021 - 07/2004
7	Adjuvant Chemotherapy 01/2019 - 09/2009
5	Cytoreduction Surgical Procedures 12/2021 - 05/2014
5	Hysterectomy 01/2019 - 08/2009
4	Lymph Node Excision (Lymph Node Dissection) 11/2021 - 08/2009
4	Neoadjuvant Therapy 09/2020 - 11/2012
3	Laparotomy 11/2016 - 12/2015
2	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 01/2013
2	Salpingo-oophorectomy 07/2017 - 08/2009
2	Length of Stay 11/2016 - 12/2015
2	Bariatric Surgery 09/2015 - 09/2014
1	Maintenance Chemotherapy 12/2022
1	Curettage 05/2020